A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors

Trial Profile

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Hyaluronidase (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 04 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Jun 2018 According to a Halozyme Therapeutics media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.
    • 01 Jun 2018 According to a Halozyme Therapeutics media release, the company has completed an enrollment in the lung cohort in the study. The company has given option to the investigators, to continue treatment of ongoing patients. Data from this study will be submitted to medical forum in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top